Penningtons Manches Cooper Advised SkinBioTherapeutics Plc On £4.6 Million Placing, Subscription, And Retail Offer On AIM
Penningtons Manches Cooper Advised SkinBioTherapeutics Plc On £4.6 Million Placing, Subscription, And Retail Offer On AIM
Penningtons Manches Cooper is advising SkinBioTherapeutics plc (AIM: SBTX) on a £4.6 million equity fundraising, comprising a placing, subscription, and a retail offer to existing shareholders through the Winterflood Retail Access Platform.
This marks the fifth AIM equity fundraising that Penningtons Manches Cooper has handled for its long-standing client SkinBioTherapeutics. Singer Capital Markets is acting as nominated adviser and broker on the transaction, which is expected to close on 24 June 2025.
SkinBioTherapeutics, a life sciences company focused on skin health, recently announced an exclusive UK commercial agreement with Superdrug Stores plc on June 16, 2025, for the distribution of its AxisBiotix™ food supplements, aimed at alleviating symptoms of inflammatory skin conditions.
The net proceeds of the fundraising will be used to support the Superdrug agreement and provide additional working capital for the business.
The Penningtons Manches Cooper team was led by Seb Orton (Partner, Corporate), with support from Jenny Wright (Associate).
Click to know more about Penningtons Manches Cooper
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.
